Equities Analysts Offer Predictions for TVRD FY2025 Earnings

Tvardi Therapeutics, Inc. (NASDAQ:TVRD - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for Tvardi Therapeutics in a note issued to investors on Friday, July 11th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the company will earn ($2.19) per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $52.00 target price on the stock.

Several other brokerages also recently issued reports on TVRD. Oppenheimer assumed coverage on Tvardi Therapeutics in a research report on Wednesday, May 21st. They issued an "outperform" rating and a $65.00 price objective on the stock. Wall Street Zen upgraded Tvardi Therapeutics to a "hold" rating in a research report on Saturday, May 24th. Finally, Piper Sandler assumed coverage on Tvardi Therapeutics in a research report on Thursday, June 12th. They issued an "overweight" rating and a $78.00 price objective on the stock.

Tvardi Therapeutics Trading Up 20.6%

Shares of NASDAQ:TVRD opened at $27.34 on Monday. Tvardi Therapeutics has a 52-week low of $8.13 and a 52-week high of $34.31.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.